LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Smith & Nephew PLC ADR

Gesloten

33.37 0.97

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

33.07

Max

33.46

Belangrijke statistieken

By Trading Economics

Inkomsten

35M

331M

Verkoop

203M

3.2B

K/W

Sectorgemiddelde

23.14

61.417

Dividendrendement

2.36

Winstmarge

10.368

Werknemers

17,000

EBITDA

133M

856M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+5.65% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.36%

2.40%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.1B

14B

Vorige openingsprijs

32.4

Vorige sluitingsprijs

33.37

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Smith & Nephew PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mrt 2026, 22:42 UTC

Winsten

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mrt 2026, 21:40 UTC

Winsten

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mrt 2026, 23:56 UTC

Marktinformatie

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mrt 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mrt 2026, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 mrt 2026, 23:42 UTC

Marktinformatie

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mrt 2026, 23:38 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mrt 2026, 23:24 UTC

Marktinformatie

Global Energy Roundup: Market Talk

17 mrt 2026, 23:24 UTC

Marktinformatie

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mrt 2026, 22:22 UTC

Marktinformatie

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mrt 2026, 22:20 UTC

Winsten

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mrt 2026, 22:20 UTC

Winsten

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mrt 2026, 22:07 UTC

Winsten

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mrt 2026, 22:05 UTC

Winsten

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mrt 2026, 22:04 UTC

Winsten

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mrt 2026, 22:03 UTC

Winsten

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mrt 2026, 21:26 UTC

Winsten

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mrt 2026, 21:09 UTC

Winsten

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mrt 2026, 21:08 UTC

Winsten

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mrt 2026, 21:08 UTC

Winsten

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mrt 2026, 21:07 UTC

Winsten

Couche-Tard 3Q EPS 82c >ATD.T

17 mrt 2026, 21:06 UTC

Winsten

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q EPS 82c >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Net $757.2M >ATD.T

17 mrt 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Energy & Utilities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC ADR Prognose

Koersdoel

By TipRanks

5.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34.96 USD  5.65%

Hoogste 35 USD

Laagste 34.91 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

26.64 / 28.37Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat